Timothy Lu Biography and Net Worth

CEO of Senti Biosciences

Dr. Lu has served as our CEO since he co-founded Senti Bio in 2016. From 2010-2022, Dr. Lu was a tenured MIT faculty member in the departments of Biological Engineering and Electrical Engineering and Computer Science. In addition, Dr. Lu has been a co-founder and a Scientific Advisory Board member to a number of biotechnology and biopharmaceutical companies, including BiomX, Corvium, Eligo Bioscience, Engine Biosciences, Synlogic and Tango Therapeutics.

Dr. Lu earned his M.D. from Harvard Medical School and his Ph.D. in Electrical and Biomedical Engineering from Massachusetts Institute of Technology as part of the Harvard-MIT Health Sciences and Technology Medical Engineering and Medical Physics Program. Dr. Lu has extensive experience in the field of synthetic biology and has received numerous awards: NIH New Innovator Award, US President Early Career Award for Scientists and Engineers, MIT Technology Review’s TR35, Navy and Army Young Investigator Prizes and others.

What is Timothy K. Lu's net worth?: The estimated net worth of Timothy K. Lu is at least $26.03 thousand as of February 4th, 2025. Lu owns 82,627 shares of Senti Biosciences stock worth more than $26,028 as of October 6th. This net worth estimate does not reflect any other assets that Lu may own. Learn More about Timothy K. Lu's net worth.
How do I contact Timothy K. Lu?: The corporate mailing address for Lu and other Senti Biosciences executives is 2 Corporate Drive, First Floor, South San Francisco, CA, 94080. Senti Biosciences can also be reached via phone at 650-239-2030 and via email at [email protected]. Learn More on Timothy K. Lu's contact information.
Has Timothy K. Lu been buying or selling shares of Senti Biosciences?: Timothy K. Lu has not been actively trading shares of Senti Biosciences during the past quarter. Most recently, Timothy K. Lu sold 545 shares of the business's stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $4.36, for a transaction totalling $2,376.20. Following the completion of the sale, the chief executive officer now directly owns 82,082 shares of the company's stock, valued at $357,877.52. Learn More on Timothy K. Lu's trading history.
Who are Senti Biosciences' active insiders?: Senti Biosciences' insider roster includes Timothy Lu (CEO), and Kanya Rajangam (Insider). Learn More on Senti Biosciences' active insiders.

Timothy K. Lu Insider Trading History at Senti Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/6/2025	Sell	545	$4.36	$2,376.20	82,082
2/4/2025	Sell	3,922	$4.07	$15,962.54	82,627

Timothy K. Lu Buying and Selling Activity at Senti Biosciences

Senti Biosciences Company Overview

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Today's Range

Now: $0.32

$0.31

$0.34

50 Day Range

MA: $0.35

$0.30

$0.46

2 Week Range

Now: $0.32

$0.29

$2.88

Volume

193,665 shs

Average Volume

319,269 shs

Market Capitalization

$10.06 million

P/E Ratio

N/A

Dividend Yield